SPOTLIGHT -
New Cabometyx-Opdivo combo for renal cell carcinoma treatment
FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).
MacroGenics treatment for HER2-positive breast cancer to be available in March
New treatment for metastatic HER2-positive breast cancer is called Margenza.
Biosimilar to Rituxan expected to hit market in January
The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.
Pharma maker expects myeloma drug approval after positive results
After positive Phase 3 trial results, Karyopharm Therapeutics expects FDA to clear Xpovio.
FDA clears novel generic thyroid cancer treatment
FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.
Cancer-linked impurity found in heartburn drug
FDA is evaluating risks to patients.
Merck’s Keytruda snags another cancer indication
FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).
Top 6 Cancer Drug Trends
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
FDA approves cabozantinib for treatment-experienced patients with aggressive liver cancer
FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.
FDA approves Tecentriq, Avastin combo for first-line treatment of lung cancer
A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.
FDA clears novel cancer treatments
Here are the top 2 novel cancer drugs cleared by the agency.
Top 3 new FDA approvals
Here are the top 3 new approvals from FDA.
Broader indication for prostate cancer drug could net billions of dollars
FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.
Cancer risk found with common blood pressure med
Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.
Cancer in the news: Three stories you can’t miss
A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.
New targeted melanoma combo drug available
A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.
Avastin gains approval for another cancer type
The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.
FDA backs new biosimilar, plus 2 more approvals
FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.
Cancer drug prices rise despite Trump plan
The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.
New treatment for advanced kidney cancer approved
FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
